Estadístiques de The McCAVE Trial: vanucizumab plus mFOLFOX-6 versus bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal carcinoma (mCRC)
Visites totals
views | |
---|---|
The McCAVE Trial: vanucizumab plus mFOLFOX-6 versus bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal carcinoma (mCRC) | 68 |
Visites totals per mes
views | |
---|---|
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
March 2025 | 3 |
April 2025 | 0 |
Visites al fitxer
views | |
---|---|
bendell-onc-them.pdf(legacy) | 138 |
bendell-onc-them.pdf | 37 |
Vistes principals per país
views | |
---|---|
United States | 49 |
Belgium | 5 |
Spain | 4 |
India | 3 |
China | 2 |
Germany | 2 |
Iran | 1 |
Malaysia | 1 |
Sweden | 1 |
Visites principals per ciutat
views | |
---|---|
San Ramon | 14 |
Ann Arbor | 6 |
Menlo Park | 6 |
Mountain View | 5 |
Ashburn | 3 |
Boardman | 2 |
San Diego | 2 |
Shenzhen | 2 |
Airoli | 1 |
Alella | 1 |
Arteixo | 1 |
Badalona | 1 |
Bangalore | 1 |
Cambridge | 1 |
Fairfield | 1 |
Fremont | 1 |
Mumbai | 1 |
Portland | 1 |
Redwood City | 1 |
Shah Alam | 1 |